Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Long-Term Safety Extension in Allergic Asthma
NCT00482508Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2003
- Primary completion
- Oct 2005
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoints: Safety assessed by adverse events, serious adverse events, vital signs and laboratory safety data at 1 year and Free and total IgE levels. Started May 2003; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00482508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482508.